<DOC>
	<DOCNO>NCT00389415</DOCNO>
	<brief_summary>This 52-week multicenter open-labeled extension study design ass long-term safety vildagliptin ( 100 mg qd ) patient Type 2 Diabetes . This extension study open patient complete core study CLAF237A1303 .</brief_summary>
	<brief_title>Long Term Safety Vildagliptin ( 100mg qd ) In Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Diagnosis Type 2 Diabetes Patients complete study CLAF237A1303 Outpatients Patients prematurely discontinue Study CLAF237A1303 Other protocoldefined inclusion/exclusioncriterial may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>HbA1c</keyword>
</DOC>